Figure 6 from Disruption of KLHL6 Fuels Oncogenic Antigen Receptor Signaling in B-Cell Lymphoma

Interrogation of CD79B at the protein level in the discovery set and KLHL6-mutated tumors. P values for comparisons between two groups in box plots are calculated with the Mann–Whitney U test. Individual channels shown for the white dashed areas are shown right to the microscopy images. A, IF microscopy image of a GC in a reactive lymph node showing the highest CD79B intensity in the mantle zone, whereas KLHL6 positivity is restricted to the GC. Scale bar, 100 µm. B and C, Box and dot plots with y-axis showing (B) quantified CD79B intensity and (C) CD79B gene expression (from RNA sequencing) according to KLHL6GC+ IHC (x-axis). D, Box and dot plots of quantified CD79B intensity according KLHL6GC+ IHC phenotype within different molecular subtypes determined by gene expression profiling. E, Representative IF microscopy images of KLHL6GC- tumors showing plasma membrane–like CD79B staining. Sections stained for CD79B, KLHL6, and DNA (DAPI) and images obtained with optical sectioning and 40× objective. Scale bar, 20 µm. F, Oncoprint of patients (columns) with KLHL6 and/or CD79B mutations (n = 23). G, Box and dot plot of CD79B intensity according to KLHL6 BTB domain encoding mutation status. Amino acid changes of all KLHL6 mutations for available cases are annotated, and the presence of CD79B mutations is indicated with a color. H, Box and dot plot showing CD79B intensity according to CD79B mutations with Y197 hot spot considered separately. Color of the dots indicates KLHL6GC IHC status and amino acid changes of CD79B mutations are annotated. I, Representative IF microscopy images of tumors with different KLHL6 mutations co-stained for CD79B, KLHL6, and DNA (DAPI). Images within dashed area indicate additional KLHL6-mutated DLBCL tumors not included in the discovery cohort. Scale bar, 20 µm applies to all images.